Citigroup Inc Cara Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 23,098 shares of CARA stock, worth $119,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,098

Previous 29,520 21.75%

Holding current value

$119,416

Previous $7,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.26 - $0.38 $1,669 - $2,440	-6,422 Reduced 21.75%	23,098 $7,000
Q2 2024 Aug 12, 2024	SELL	$0.24 - $0.92 $5,643 - $21,632	-23,514 Reduced 44.34%	29,520 $7,000
Q1 2024 May 10, 2024	BUY	$0.52 - $1.05 $1,266 - $2,556	2,435 Added 4.81%	53,034 $48,000
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.65 $3,466 - $9,533	5,778 Added 12.89%	50,599 $37,000
Q3 2023 Nov 09, 2023	SELL	$1.67 - $3.33 $23,582 - $47,022	-14,121 Reduced 23.96%	44,821 $75,000
Q2 2023 Aug 10, 2023	SELL	$2.83 - $4.94 $32,808 - $57,269	-11,593 Reduced 16.44%	58,942 $166,000
Q1 2023 May 11, 2023	SELL	$4.89 - $12.27 $17,383 - $43,619	-3,555 Reduced 4.8%	70,535 $346,000
Q4 2022 Feb 09, 2023	BUY	$8.88 - $12.77 $8,498 - $12,220	957 Added 1.31%	74,090 $795,000
Q3 2022 Nov 10, 2022	SELL	$8.24 - $12.56 $47,248 - $72,019	-5,734 Reduced 7.27%	73,133 $685,000
Q2 2022 Aug 10, 2022	SELL	$7.45 - $13.84 $55,897 - $103,841	-7,503 Reduced 8.69%	78,867 $720,000
Q1 2022 May 12, 2022	BUY	$9.94 - $12.65 $46,260 - $58,873	4,654 Added 5.7%	86,370 $1.05 Million
Q4 2021 Feb 10, 2022	BUY	$11.99 - $18.14 $450,907 - $682,190	37,607 Added 85.26%	81,716 $995,000
Q3 2021 Nov 10, 2021	BUY	$11.55 - $16.06 $509,458 - $708,390	44,109 New	44,109 $681,000

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $278M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account